Eli Lilly’s cost-saving argument for Zepbound runs into a price gap in a new analysis

Eli Lilly’s case that its weight-loss drug Zepbound can generate meaningful cost savings for the broader health system is being challenged on a basic accounting point, according to a Yahoo Finance analysis published Tuesday.

The article says Lilly’s argument, built around a “cost-saving study,” appears compelling from a payer perspective, but the way the savings are measured leaves out the medicine’s price. In other words, the analysis focuses on reductions in medical spending first, then does not incorporate what payers would actually pay for the drug to achieve those outcomes.

The crux of the critique is timing and structure. The Yahoo Finance review describes the study as measuring “medical savings” without first charging for the Zepbound medication itself, which can overstate net savings in real-world reimbursement settings where drug acquisition costs matter as much as downstream utilization changes.

That matters because weight-loss therapies like Zepbound are typically evaluated not only on clinical outcomes but also on total cost of care, which includes both the drug spend and the offsetting medical costs. If drug pricing is excluded from the savings calculation, the resulting net benefit can look larger on paper than it would in a plan sponsor’s budget.

Zepbound is the brand name for tirzepatide, a medicine used for chronic weight management. Lilly’s commercial and policy discussions around such drugs often hinge on whether payers view the higher pharmacy spend as justified by lower medical costs over time, an evaluation that depends heavily on how studies treat pricing.

The Yahoo Finance piece also implies that this omission could affect how stakeholders interpret the study’s relevance to coverage decisions. For health plans and other payers, affordability is not only about clinical improvement but also about whether those improvements translate into measurable savings after considering the cost of getting the drug to patients.

Eli Lilly did not provide additional disclosures in the Yahoo Finance write-up beyond the characterization of the study’s methodology. The article does not, in the excerpt available here, specify alternative analyses that incorporate Zepbound’s price, nor does it quantify the magnitude of net-savings changes under different cost assumptions.

What to watch next is whether Lilly, or other parties reviewing the evidence, publish revised or supplementary cost-effectiveness framing that explicitly includes drug price, rebates, utilization assumptions, and the time horizon over which medical offsets are expected to occur. Without that, debate over the net fiscal impact is likely to continue.